| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -33,440 | -21,546 |
| Depreciation expense | 3 | - |
| Stock-based compensation expense | 1,603 | 965 |
| Change in fair value of derivative liabilities (including 1,165 and 860 for a related party) | 1,229 | 1,229 |
| Change in fair value of tranche liability (including 331 and 0 for a related party) | 365 | 365 |
| Non-cash interest expense (including 1,384 and 1,392 for a related party) | 1,443 | 1,443 |
| Non-cash operating lease expense | -12 | - |
| Net amortization of premiums and accretion of discounts on investments | 83 | - |
| Loss on extinguishment and on issuance of convertible promissory notes (including 169 and 2,134 for a related party) | -186 | -186 |
| Prepaid expense and other current assets | -1,453 | 588 |
| Other non-current assets | 370 | 281 |
| Accrued compensation | - | -1,073 |
| Accounts payable | -962 | 2,240 |
| Accrued expenses and other current liabilities (including 20 and 36 for a related party) | 419 | 268 |
| Operating lease liabilities | 17 | - |
| Net cash used in operating activities | -31,313 | -19,980 |
| Purchase of short-term investments | 34,523 | - |
| Purchase of property and equipment | 183 | - |
| Net cash used in investing activities | -34,706 | - |
| Proceeds from the issuance of convertible promissory notes (including 3,402 and 9,993 from a related party), net of issuance costs | 7,500 | 7,500 |
| Cash acquired in connection with the merger | 102,113 | 102,113 |
| Payment of deferred transaction costs and issuance costs | 2,346 | 2,346 |
| Net cash provided by financing activities | 107,267 | 107,267 |
| Net increase (decrease) in cash and cash equivalents and restricted cash | 41,248 | 87,287 |
| Cash and cash equivalents at beginning of period | 1,639 | - |
| Cash and cash equivalents at end of period | 42,887 | - |
Kalaris Therapeutics, Inc. (KLRS)
Kalaris Therapeutics, Inc. (KLRS)